Therefore, modalities to achieve specific and appropriate levels of PINK1-PARK2-mediated mitophagy activation may be a promising therapeutic option to regulate the aging-associated pathology, COPD and IPF. The gene discussed is PRKN; the disease is idiopathic pulmonary fibrosis.